Proteros biostructures GmbH and Eisai Company, Ltd. (ESALY.PK) Achieve Target in Lead Discovery Project, Delivering Kinetically Optimized Lead Compounds
5/6/2013 11:24:15 AM
More...
|
Eisai Company, Ltd. (ESALY.PK) to Establish New Parenteral Facility in China
4/25/2013 8:16:37 AM
More...
|
Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Company, Ltd. (ESALY.PK) Product Creation Systems
4/11/2013 7:46:37 AM
More...
|
Eisai Inc. (ESALF.PK) Announces Launch of Chocola BB(R) Sparkling + Fiber, Containing 5 Ingredients that Help Bring Out Beauty From Within
3/22/2013 9:52:16 AM
More...
|
Eisai Company, Ltd. (ESALY.PK)'s Farletuzumab Fails Ovarian Cancer Trial
1/14/2013 10:14:46 AM
More...
|
Eisai Company, Ltd. (ESALY.PK)'s Epilepsy Drug Helps Obese Patients Lose Weight
10/17/2012 7:36:52 AM
More...
|
Eisai Company, Ltd. (ESALY.PK) Partners With the Sabin Vaccine Institute in an Effort to Develop Vaccines for Neglected Tropical Diseases
9/27/2012 4:20:14 PM
More...
|
Eisai Company, Ltd. (ESALY.PK) Opens New Solid Dose Global Manufacturing Line for Antiepileptic Agent Fycompa® at Its Production Plant in Hatfield, U.K.
9/27/2012 4:17:22 PM
More...
|
Eisai Company, Ltd. (ESALY.PK) and Santen Pharmaceutical Enter Into Option Agreement for New Ophthalmic Drugs
9/27/2012 4:14:34 PM
More...
|
Eisai Company, Ltd. (ESALY.PK) Receives Approval to Market Anticancer Agent Halaven® in Australia
9/10/2012 9:59:04 AM
More...
|
|